Eye injection treatment costs and rebates

Similar documents
Eye injection treatment costs and rebates

Ophthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description

Changes to Australian Government Hearing Services Program and Voucher scheme

Treatment of Age Related Macular Degeneration (AMD) by Intravitreal Injection

Age-Related Macular Degeneration (AMD)

CONCEPT DOES NOT REQUIRE AN UP FRONT DEPOSIT (Except for Standard IVF/ICSI/FET where out of pocket costs must be paid in advance)

Coding Implications Revision Log. See Important Reminder at the end of this policy for important regulatory and legal information.

Intravitreal Injection

HOW TO PICK THE RIGHT OCT

Information for Patients undergoing Intravitreal Triamcinolone Acetonide (Kenalog) Injection

Photodynamic therapy (PDT) for Central Serous Retinopathy (CSR)/ Polypoidal Choroidal Vasculopathy (PCV)

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

Writing a PBS-RPBS prescription authorised optometrists


Medical gap arrangements - practitioner application

Diabetic Retinopathy A Presentation for the Public

Introduction How the eye works

and at the same patient encounter. Code has been deleted. For scanning computerized ophthalmic diagnostic imaging of optic nerve and retin

Photodynamic Therapy (PDT) for agerelated

Clinical Policy: Aflibercept (Eylea) Reference Number: CP.PHAR.184

The Human Eye. Cornea Iris. Pupil. Lens. Retina

Information for patients


GENERAL INFORMATION DIABETIC EYE DISEASE

Age-related Macular Degeneration (AMD) treatment information

A Patient s Guide to Diabetic Retinopathy

See Important Reminder at the end of this policy for important regulatory and legal information.

Ophthalmologic Policy. Vascular Endothelial Growth Factor (VEGF) Inhibitors

Updates to the Alberta Drug Benefit List. Effective August 1, 2017

Your Guide to Extras Cover

The College of Optometrists - Learning outcomes for the Professional Certificate in Medical Retina

Treatment of Retinal Vein Occlusion (RVO)

RETINAL CONDITIONS RETINAL CONDITIONS

Senate Submission. Out of pocket costs in Australian hearing health care June 2014


Common Drug Review Patient Group Input Submissions

Ophthalmology Unit Referral Guidelines

Major new Macular Degeneration Foundation research initiative

Clinically Significant Macular Edema (CSME)

DIABETIC RETINOPATHY

Brampton Hurontario Street Brampton, ON L6Y 0P6

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May

04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint

Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial

Facts About Diabetic Eye Disease

aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer

Billing Requirements for Intravitreal Injections. Financial Interest. Indications. Documentation. Documentation. Documentation

Setting The setting was a hospital. The economic study was conducted in the USA.

Spotlight on SF0166: topical eye droplet treatment for retinal diseases DME and wet-amd

THE ECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN A WORKING AGE AND COMMERCIALLY INSURED POPULATION. Christopher John Wallick

Please read this Policy Summary carefully and retain it for future reference.

Vision and eye healthcare study in residential aged care facilities

There are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.

The Economic$ and Epidemiology of Intravitreal Injections

04/06/2015. Documentation Do s and Don ts In The Retina Practice. Financial Disclosure. Documentation Dos and Don ts

Extras Cover Special Options

Date approved: 04/18/18. Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy

Basic Extras Cover. Effective 1 April 2017 v.2

Guide to Dental Benefit Plans

Diagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City

OPHTHALMOLOGIC POLICY: VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS

Caregiver s guide to wet AMD

VEGF-C shown to have major role in Age-Related Macular Degeneration (AMD)

How the eye works. Causes of retinitis pigmentosa

Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)

The legally binding text is the original French version

(with Orthodontics) Summary of Benefits

The Foundation WHAT IS THE RETINA? continued next page. RETINA HEALTH SERIES Facts from the ASRS

Retinal Complications of Obstructive Sleep Apnea A Growing Concern!

EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY

Results & Treatment Costs

Dan Roberts. International Low Vision Support Group NEWSLETTER. This Month. In This Issue. 1: This Month 2-5: News

Silver Extras Set Benefits

Fundamentals of Retina Coding

A Reason to Smile. Dental Care with No Surprises. Dental insurance underwritten by: Mutual of Omaha Insurance Company

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema

Palliative Care & Private Health Insurance

If you would like further information, please ask any of the staff at the clinic. They will be happy to help.

Recalcitrant Diabetic Macular Oedema: Therapeutic Options

NSW Medical Energy Rebate

EyeGene Inc. Contact Information Korea Health Industry Development Institute

Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?

Breast Cancer Network Australia Herceptin and Heart Health Survey November 2010

Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema

Will OCT-Angiography replace FA?

Breast Cancer Network Australia DXA bone mineral density survey May 2012

Winnipeg Regional Health Authority / Oral Health Program

Management of Neovascular AMD

We are a dedicated skin clinic with specialized equipments and staff. We only deal with skin and skin cancer.

The Foundation. continued next page. RETINA HEALTH SERIES Facts from the ASRS

Cost projections a single antiretroviral co-payment scheme for people with HIV in NSW. March 2013

Diabetic Retinopathy What You Should Know. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Eye Institute

SURGICAL VITREORETINAL FELLOWSHIP PROGRAM. UNIVERSITY OF KENTUCKY AND RETINA ASSOCIATES OF KENTUCKY Lexington, Kentucky

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

Attention Deficit (Hyperactivity) Disorder What you need to know in 12 pages!

Dr. Harvey Richman, OD, FAAO, FCOVD Diplomate American Board of Optometry Executive Committee AOA Third Party Center Founder Ask the AOA Coding

VISITING YOUR LOCAL GP PRACTICE: A GUIDE

The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care

GUIDE TO BUYING HEARING AIDS

Transcription:

Eye injection treatment costs and rebates This fact sheet provides general information on the bill you receive from your ophthalmologist for eye injections for the management of wet macular degeneration, diabetic retinopathy and similar conditions. It also gives some general information on your entitlements from Medicare. As ophthalmologists are entitled to set their own fees, this fact sheet cannot provide specific information or precise rebates for your individual situation. You should ask your ophthalmologist for written details on the fees and charges you will incur for consultations, tests and treatment. If the costs are going to place you under financial difficulty and possibly compromise your treatment plan, you should discuss this with your doctor. The fees you pay may involve up to four areas: consultation, diagnostic tests, drug costs and injection costs. In some cases (especially for diabetic retinopathy), you may also be billed for laser treatment. Doctors may list and describe the items and cost on the bill in varying ways. The Foundation has highlighted in blue bold throughout the factsheet the Medicare item numbers and descriptors that may most likely be used. In this fact sheet the term doctor means the ophthalmologist. Consultations Medicare item 104 - Initial consultation: This item applies when you first visit the doctor for a specific condition. Medicare item 105 - Subsequent consultation: This item applies for ongoing consultations. Diagnostic tests a) Fundus fluorescein angiography (also known as angiogram or FFA) Medicare item 11215 (one eye) or item 11218 (two eyes) - Retinal photography, including intravenous dye examination This test checks for bleeding or leakage under the retina. It is required before you first start injections in order to qualify for Pharmaceutical Benefits Scheme (PBS) reimbursement of the drug that is used to treat the bleeding or leakage. It may also be done to check for new leakage. b) Ocular coherence tomography (OCT): Medicare item 11219 An OCT scan shows the cross-sectional layers of the retina and is initially performed to confirm a diagnosis and measure how much swelling has occurred. OCT scans will typically be undertaken on a regular basis while on a course of injections in order to monitor response to treatment. OCT scans are now internationally recognised as the standard of care to monitor response to injections. From November 2016, up to one OCT scan per year may be reimbursed by Medicare, but only when the scan is performed by an ophthalmologist for an initial diagnosis to confirm eligibility for PBS-funded eye injections. OCT scans for ongoing monitoring of disease are not currently reimbursed by Medicare. c) Other tests: Depending on individual needs, other tests may be undertaken.

Drug costs The cost of the drug is in addition to the diagnostic and injection fees. a) Lucentis and Eylea The drugs Lucentis and Eylea are registered by the Therapeutic Goods Administration (TGA) and are subsidised by the Pharmaceutical Benefits Scheme (PBS) for the treatment of: Wet age-related macular degeneration (AMD) Diabetic macula edema (DME) Retinal vein occlusion (RVO) Under the PBS, the subsidised cost of these drugs in 2017 per prescription (1 dose) is: $6.30 (concession card holder); or $38.80 (non-concession) The PBS Safety Net will apply once the costs in a calendar year for all PBS drugs exceed $378.00 (concession) or $1,494.90 (non-concession). After reaching the PBS Safety Net, each subsequent PBS script will be free (concession) or $6.30 (non-concession) for the remainder of the calendar year. b) Avastin For those who do not qualify for PBS subsidised drugs, the drug Avastin may be used. Avastin is not registered by the TGA for use in the eye. This is known as off-label use and it is not subsidised by the PBS for these conditions. The cost of Avastin typically ranges between $50 and $80 per dose. Treatment procedures Injection procedure Either of two Medicare items may be used for the injection procedure. Medicare item 42738 Intra-vitreal injection: This may appear on the bill as Paracentesis or Injection. Medicare item 42739 Intra-vitreal injection: This item number will be used if you require sedation or a general anaesthetic, where an anaesthetist is present. This may also appear on your bill as Paracentesis or Injection. Laser procedure In some cases, laser treatment may be used. Medicare item 42809 - Retina photocoagulation

Medicare benefits Medicare provides significant benefits (rebates) for many of the items related to eye injections. The benefit is normally paid: in doctors rooms: as 85% of the schedule fee in a private hospital or day case setting: as 75% of the schedule fee Table 1: Current Medicare Benefits Item Description Schedule fee 85% benefit (in-rooms) 75% benefit (private hospital) 104 Initial consultation $85.55 $72.75 $64.20 105 Subsequent consultation $43.00 $36.55 $32.25 11215 Angiogram (one eye) $123.00 $104.55 $92.25 11218 Angiogram (two eyes) $151.75 $129.20 $114.00 11219 Optical coherence tomography (OCT) (initial diagnosis only) $40.00 $34.00 $30.00 42738 Injection fee $300.75 $255.65 $225.60 42739 Injection w/ sedation/anaesthetic $300.75 $255.65 $225.60 42809 Retina photocoagulation (laser) $451.10 $383.45 $338.35 Note: For injections in both eyes on the same day, the benefit for the second eye is reduced by 50%. If two eyes are treated on separate days, the normal benefits apply. OCT scans will only be reimbursed for an initial diagnosis to confirm eligibility for PBS-funded eye injections, with a maximum of one reimbursement per year. Original Medicare Safety Net The difference between the schedule fee and the benefit paid by Medicare is known as the gap amount. The gap amount for an eye injection given in the doctor s rooms is currently $45.10. This is calculated as the schedule fee ($300.75) minus Medicare benefit ($255.65). (Refer to Table 1) Once the total gap amount for all Medicare items exceeds the Original Medicare Safety Net threshold* in a calendar year, the Original Medicare Safety Net will refund 100% of the schedule fee for subsequent Medicare items. For example, for Item 42738 (Injection fee), you would receive a benefit of $300.75. * The Original Medicare Safety Net threshold is set by the Australian Government and changes from time to time. In 2017 the threshold is $453.20.

Out-of-pocket costs Doctors may charge more than the Medicare schedule fee. The difference between what the doctor charges and the Medicare benefit is known as the out-of-pocket cost. This is different to the gap amount. Example: Note: Costs vary between doctors. The following is an example only. If a doctor charges $100 for a subsequent consultation (Item 105) and $400 for an in-rooms injection (Item 42738), the out-of-pocket costs for these will be as follows (in red): Table 2: Example of out-of-pocket costs Service Item Ophthal charge (a) Schedule fee (b) Medicare benefit (c) (85% of (b)) Out of pocket cost per visit (a)-(c) Subsequent consultation fee 105 $100.00 $43.00 $36.55 $63.45 Injection fee 42738 $400.00 $300.75 $255.65 $144.35 $500.00 $292.20 $207.80 If the Original Medicare Safety Net has also been reached, the out-of-pocket costs would be further reduced. Extended Medicare Safety Net Once the total out-of-pocket costs for all non-hospital Medicare items exceed a certain threshold + in a calendar year, the Extended Medicare Safety Net (EMSN) will refund the relevant Medicare benefit PLUS a further benefit of 80% of out-of-pocket costs for Medicare items. + The Extended Medicare Safety Net thresholds are set by the Australian Government and change from time to time. In 2017, the thresholds for out-of-pocket costs are: Concession card holders: $656.30 Non-concession: $2,056.30 Example: Using the same charges as Table 2, once the EMSN threshold has been reached, the total benefit paid for the injection (Item 42738) would equal the normal Medicare benefit of $255.65 plus the EMSN benefit of $115.50 (being 80% of the out-of-pocket amount of $144.35), giving a total benefit of $371.15. This means you would only pay $28.85 for that item after you have received all the rebates.

Table 3: Example of benefits and out-of-pocket costs that may apply once the EMSN threshold has been reached Service Item Ophthal charge (a) Medicare benefit (b) OOP costs before EMSN threshold (c) (a-b) EMSN benefit (80% of OOP costs) (d) (80% of (c)) Out-of-pocket costs after reaching Extended Medicare Safety Net threshold (a)-(b)-(d) Subsequent consultation fee 105 $100.00 $36.55 $63.45 $50.75 $12.70 (20% of OOP) Injection fee 42738 $400.00 $255.65 $144.35 $115.50 $28.85 (20% of OOP) $500.00 $207.80 $166.25 $41.55 (OOP = out of pocket) If the Original Medicare Safety Net had also been reached, the benefits would be slightly higher. For some procedures, including eye injections, the EMSN benefits are capped. Note: Other than when used for an initial diagnosis to confirm eligibility for PBS-funded injections, OCT scans do not attract any Medicare benefits and do not contribute towards the Original or Extended Medicare Safety Net threshold. Procedures performed in a private hospital or day surgery setting do not contribute towards the EMSN threshold and do not receive the additional 80% EMSN benefits. Registration for Medicare Safety Net Couples and families need to register as a Medicare Safety Net family, even if all are listed on the same Medicare card. Medicare will automatically keep a total of your gap amounts and out-of-pocket medical expenses. Registration is free and you only need to register once in your lifetime. To register for the Medicare Safety Net: Download a Medicare Safety Net couples and families registration and amendment form from www.humanservices.gov.au Visit your local Medicare office Call Medicare 132 011 Department of Veterans Affairs (DVA) patients DVA gold card holders may qualify for some additional rebates, including additional OCT scans.

Treatment in hospital Treatment in public hospitals A limited number of public hospitals provide outpatient treatment for conditions including macular degeneration and diabetic retinopathy. There should be no charge for treatment and diagnostic tests, although in some states, there may be a requirement to pay the PBS cocontribution if Lucentis or Eylea are used ($6.30 concession or $38.80 non-concession). Treatment in private hospitals In some situations, a doctor may decide to give injections in a private hospital or day surgery setting. People who hold private health insurance may be able to claim from their private health fund for the procedure and accommodation charge. This is dependent on the insurer and the policy. Important points Injections are typically required for an extended period (many years), and possibly for life. You should obtain a written estimate of fees, Medicare benefits and out-of-pocket costs from your doctor. If you have financial difficulty with treatment costs, discuss your concerns with your doctor or the appointed person in the practice. Treatment should not be stopped without discussion with the doctor. There may be a number of challenges with maintaining treatment, including costs or transport or other health issues. Discuss your concerns with your doctor. If you require further information, clarification or guidance on eye injection treatment and benefits or related matters please contact: Macular Disease Foundation Australia Suite 902, 447 Kent St Sydney NSW 2000 Phone: 1800 111 709 Email: info@mdfoundation.com.au Web: www.mdfoundation.com.au January 2017 Disclaimer: Information contained in this fact sheet is considered by the Macular Disease Foundation Australia to be accurate at the time of publication. While every care has been taken in its preparation, medical advice should be sought from a doctor. The Macular Disease Foundation Australia cannot be liable for any error or omission in this publication or for damages arising from its supply, performance or use, and makes no warranty of any kind, either expressed or implied in relation to this publication.